FGF19 elevation

P=N/A, N=210, Recruiting, University of Central Florida

We further show that HCC patients with high levels of circulating FGF19 have a reduced natremia, indicating dipsogenic features. The present study provides evidence of a new activity of FGF19, which could be clinically relevant in the context of FGF19 overexpressing cancers and in the course of treatment of metabolic disorders by FGF19 analogues.

Earlier studies reporting reductions in inflammation and fibrosis utilized AAV serotype 9, a vector with broader tropism than the AAV8 used in this experiment that has primary tropism for hepatocytes. Future studies will examine these questions and compare effects on disease amelioration with novel candidates identified by our in vivo, high throughput, screening platform.

We demonstrated unfavorable prognostic effect of ORAOV1 expression with supporting experimental data in HCC. ORAOV1 may be used as a biomarker for predicting HCC prognosis and is a potential candidate for targeted therapy.